About (original) (raw)

TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. _TME Pharma’_s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.

Press Release 2024, December 2308:00 a.m.TME Pharma announces successful completion of Euro 2.6 million public offer with strong shareholder support2024, December 2006:00 p.m.TME Pharma provides results of fourth exercise of Warrants Z2024, December 1208:00 a.m.TME Pharma announces the launch of fully guaranteed public offer for Euro 2.6 million open only to shareholders to enable completion of strategic transactions by June 2025 Events Allinvest Securities Biomed ForumAram Mangasarian, Ewelina StaniukFebruary 4, 2025 | Paris, France Latest Analyst Report Invest SecuritiesJamila El Bougrini, PhD2025, January 07 (EN/FR)